For the main guidelines analysis, we estimated the health benefits and economic impacts of 6-monthly HCC surveillance with US, with or without AFP testing, versus no routine HCC surveillance as the comparator (status quo for people with cirrhosis in Australia15). The gene discussed is AFP; the disease is Cirrhosis.